Philipp Gruber1,2, Martin Hlavica1, Jatta Berberat1, Benjamin Victor Ineichen3,4, Michael Diepers1, Krassen Nedeltchev2, Timo Kahles2, Luca Remonda5. 1. 1 Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, Switzerland. 2. 2 Department of Neurology, Cantonal Hospital Aarau, Aarau, Switzerland. 3. 3 Brain Research Institute, University of Zurich, Zurich, Switzerland. 4. 4 Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland. 5. 5 Department of Neuroradiology, Cantonal Hospital Aarau, Aarau, University of Bern, Switzerland.
Abstract
BACKGROUND: Carotid artery stenting requires antiplatelet therapy for prevention of in-stent thrombosis. Patients suffering from acute ischemic stroke undergoing intravenous thrombolysis and emergent carotid artery stenting (eCAS) are at high risk for intracranial bleeding. We assessed efficacy and safety of acute administration of intravenous tirofiban versus aspirin in these patients. METHODS: A retrospective, single center, cohort study was carried out of 32 patients who underwent eCAS (18 received tirofiban, 14 received aspirin) at our comprehensive stroke center (2008-2016). RESULTS: Of our 32 consecutive eCAS patients, favorable clinical outcomes (modified Rankin scale ≤ 2) were achieved in eight (47%) tirofiban patients and six (46%) aspirin patients ( p = 0.96). Overall rates were similar for symptomatic intracranial bleeding (tirofiban 22%, aspirin 29%, p = 0.68) and mortality (tirofiban 18%, aspirin 23%, p = 0.71). CONCLUSIONS: Tirofiban and aspirin demonstrated similar efficacy and safety in thrombolyzed stroke patients who underwent eCAS in our cohort. Intravenous tirofiban with its short half-life might represent an alternative to aspirin in select patients.
BACKGROUND: Carotid artery stenting requires antiplatelet therapy for prevention of in-stent thrombosis. Patients suffering from acute ischemic stroke undergoing intravenous thrombolysis and emergent carotid artery stenting (eCAS) are at high risk for intracranial bleeding. We assessed efficacy and safety of acute administration of intravenous tirofiban versus aspirin in these patients. METHODS: A retrospective, single center, cohort study was carried out of 32 patients who underwent eCAS (18 received tirofiban, 14 received aspirin) at our comprehensive stroke center (2008-2016). RESULTS: Of our 32 consecutive eCAS patients, favorable clinical outcomes (modified Rankin scale ≤ 2) were achieved in eight (47%) tirofibanpatients and six (46%) aspirinpatients ( p = 0.96). Overall rates were similar for symptomatic intracranial bleeding (tirofiban 22%, aspirin 29%, p = 0.68) and mortality (tirofiban 18%, aspirin 23%, p = 0.71). CONCLUSIONS:Tirofiban and aspirin demonstrated similar efficacy and safety in thrombolyzed strokepatients who underwent eCAS in our cohort. Intravenous tirofiban with its short half-life might represent an alternative to aspirin in select patients.
Authors: Amer M Malik; Nirav A Vora; Ridwan Lin; Syed F Zaidi; Aitziber Aleu; Brian T Jankowitz; Mouhammad A Jumaa; Vivek K Reddy; Maxim D Hammer; Lawrence R Wechsler; Michael B Horowitz; Tudor G Jovin Journal: Stroke Date: 2011-04-21 Impact factor: 7.914
Authors: Thomas G Brott; Jonathan L Halperin; Suhny Abbara; J Michael Bacharach; John D Barr; Ruth L Bush; Christopher U Cates; Mark A Creager; Susan B Fowler; Gary Friday; Vicki S Hertzberg; E Bruce McIff; Wesley S Moore; Peter D Panagos; Thomas S Riles; Robert H Rosenwasser; Allen J Taylor Journal: Stroke Date: 2011-01-31 Impact factor: 7.914
Authors: A J Grau; C Weimar; F Buggle; A Heinrich; M Goertler; S Neumaier; J Glahn; T Brandt; W Hacke; H C Diener Journal: Stroke Date: 2001-11 Impact factor: 7.914
Authors: Matthew B Maas; Michael H Lev; Hakan Ay; Aneesh B Singhal; David M Greer; Wade S Smith; Gordon J Harris; Elkan Halpern; André Kemmling; Walter J Koroshetz; Karen L Furie Journal: Stroke Date: 2009-07-09 Impact factor: 7.914
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Randall T Higashida; Anthony J Furlan; Heidi Roberts; Thomas Tomsick; Buddy Connors; John Barr; William Dillon; Steven Warach; Joseph Broderick; Barbara Tilley; David Sacks Journal: Stroke Date: 2003-07-17 Impact factor: 7.914
Authors: R Zahn; T Ischinger; M Hochadel; B Mark; U Zeymer; J Jung; A Schramm; K E Hauptmann; H Seggewiss; I Janicke; H Mudra; J Senges Journal: Clin Res Cardiol Date: 2007-06-27 Impact factor: 5.460
Authors: Harold P Adams; Mark B Effron; James Torner; Antoni Dávalos; Judith Frayne; Philip Teal; Jacques Leclerc; Barry Oemar; Lakshmi Padgett; Elliot S Barnathan; Werner Hacke Journal: Stroke Date: 2007-11-21 Impact factor: 7.914
Authors: J R Sims; L Rezai Gharai; P W Schaefer; M Vangel; E S Rosenthal; M H Lev; L H Schwamm Journal: Neurology Date: 2009-06-16 Impact factor: 9.910
Authors: Darko Quispe-Orozco; Kaustubh Limaye; Cynthia B Zevallos; Mudassir Farooqui; Alan Mendez-Ruiz; Sameer Ansari; Andres Dajles; Edgar A Samaniego; Colin Derdeyn; Santiago Ortega-Gutierrez Journal: Interv Neuroradiol Date: 2020-12-06 Impact factor: 1.764